Drugs / BPI-1178
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06362980 | May 2024 → Apr 2025 overdue | non-small cell lung carcinoma | National Cancer Center, China | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04282031 | Jun 2020 → Dec 2024 overdue | hormone receptor-positive breast cancer | Beta Pharma (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPI-1178 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04282031 ↗ |
| Action | Inhibit | “BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4（CDK4）and CDK6 kinase activity.” NCT04282031 ↗ |
| Route | Oral | “oral BPI-1178” NCT04282031 ↗ |
| Target | CDK4 | “BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4（CDK4）and CDK6 kinase activity.” NCT04282031 ↗ |
| Target | CDK6 | “BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4（CDK4）and CDK6 kinase activity.” NCT04282031 ↗ |